Autoimmune Diseases clinical trials

Explore recruiting autoimmune diseases clinical trials.

Recruiting autoimmune diseases studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Autoimmune Diseases trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Pharmacokinetic/pharmacodynamic evaluation of ublituximab in patients with autoimmune diseases

Poland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

FT819 in B-cell Mediated Autoimmune Diseases

France, Sweden, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Anti-CD19 CAR T-Cell TherApy in Refractory Systemic Autoimmune DISeases - CATARSIS

Italy

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Single and multiple ascending dose of ZP9830 in healthy participants

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Investigating the (autoreactive) B cell compartment in antibody-mediated autoimmune diseases in comparison with the recall Tetanus Toxoid response

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases

Germany, Romania, France, Spain, Czechia, Poland

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Autoimmune Diseases trials by city

Autoimmune Diseases clinical trials

Recruiting autoimmune diseases studies right now

A Study of AZD0120 in Autoimmune Diseases

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial

Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease

UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Post-marketing Re-evaluation of WangBi Granules for Rheumatoid Arthritis

Isolated Versus Combined Cognitive and Motor High-tech Rehabilitation

Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis

A Palliative Care Model Impact on Knowledge and Attitudes

A Study of GenSci098 in Subjects With Active Thyroid Eye Disease

Also recruiting in Europe

Pharmacokinetic/pharmacodynamic evaluation of ublituximab in patients with autoimmune diseases

FT819 in B-cell Mediated Autoimmune Diseases

Anti-CD19 CAR T-Cell TherApy in Refractory Systemic Autoimmune DISeases - CATARSIS

Single and multiple ascending dose of ZP9830 in healthy participants

Investigating the (autoreactive) B cell compartment in antibody-mediated autoimmune diseases in comparison with the recall Tetanus Toxoid response

A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases

Autoimmune Diseases trials by city

Other conditions